ArticleTranslational oncology2026
A positive feedback loop between CDH11 and TGF-β signaling regulates migration and invasion of gastric cancer.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the molecular functions and underlying mechanisms of cadherin 11 (CDH11) in the pathogenesis of advanced gastric cancer (GC), and to evaluate the therapeutic potential of targeting CDH11 and its associated signaling pathways.
methodsThe clinicopathological significance of CDH11 in GC was analyzed using the TCGA database. Experiments were conducted to assess the impact of genetic variations on the function of GC cell lines. The therapeutic potential of targeting CDH11 was evaluated in vitro and in vivo. The clinical relevance of CDH11 expression was further validated.
resultsTCGA analysis showed that CDH11 was highly expressed in GC and served as an independent prognostic biomarker. High CDH11 expression was also associated with a potentially immunosuppressive tumor microenvironment (TME) in GC. Mechanistically, CDH11 promoted epithelial-mesenchymal transition (EMT) and GC progression by upregulating TGF-β1 and activating TGF-β signaling. Activated TGF-β signaling enhanced CDH11 transcription via the binding of the downstream transcription factor Snail2 to the CDH11 promoter, thereby forming a positive regulatory loop. The targeting of CDH11/TGF-β signaling significantly suppressed migration and invasion of GC in vitro and lung metastasis of GC in vivo. Clinically, CDH11 and Vimentin were highly expressed in GC, especially in the diffuse-type cases, and a positive correlation between them was also identified. In the clinical samples, CDH11 was positively correlated with M2 macrophage marker CD163 and immune checkpoint PD-L1.
conclusionThe present study identifies a novel positive feedback loop between CDH11 and TGF-β signaling, which critically regulates EMT, migration, invasion and metastasis of GC cells. The targeting of this axis may represent a promising therapeutic strategy for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.